AstraZeneca Aktiebolag
Records under this name other than patents AstraZeneca Aktiebolag holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to AstraZeneca Aktiebolag
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,376,398 | Carboxylic acid compounds Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,150,743 | Carboxylic acid compounds Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,562,861 | Carboxylic acid compounds Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,299,465 | Carboxylic acid compounds Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,597,397 | Adenine Conjugate Compounds and Their Use as Vaccine Adjuvants Formerly held In force · High confidence | In force | High confidence | |
| US 8,012,964 | 9-substituted 8-oxoadenine compound Formerly held Term ended Term ended Aug 18, 2026 · USPTO record | Term ended | Term ended Aug 18, 2026 | USPTO record |
| US 8,575,180 | 9-substituted 8-oxoadenine compound Formerly held Term ended Ended no later than Mar 24, 2025 · USPTO record | Term ended | Ended no later than Mar 24, 2025 | USPTO record |
| US 8,969,362 | 9-Substituted 8-Oxoadenine Compound Formerly held Term ended Term ended Mar 24, 2025 · Medium confidence | Term ended | Term ended Mar 24, 2025 | Medium confidence |
| US 8,865,896 | Method for preparing adenine compound Formerly held Lapsed on the fee record Ended Oct 21, 2018 · USPTO record | Lapsed on the fee record | Ended Oct 21, 2018 | USPTO record |
| US 8,461,211 | New Use for Budesonide and Formoterol Formerly held Term ended Term ended Sep 9, 2018 · Medium confidence | Term ended | Term ended Sep 9, 2018 | Medium confidence |